TTY Biopharm Co Ltd (4105) - Total Assets
Based on the latest financial reports, TTY Biopharm Co Ltd (4105) holds total assets worth NT$11.35 Billion TWD (≈ $357.53 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 4105 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
TTY Biopharm Co Ltd - Total Assets Trend (2017–2025)
This chart illustrates how TTY Biopharm Co Ltd's total assets have evolved over time, based on quarterly financial data. Check 4105 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
TTY Biopharm Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
TTY Biopharm Co Ltd's total assets of NT$11.35 Billion consist of 53.0% current assets and 47.1% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 22.2% |
| Accounts Receivable | NT$1.50 Billion | 13.2% |
| Inventory | NT$1.39 Billion | 12.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how TTY Biopharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TTY Biopharm Co Ltd (4105) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TTY Biopharm Co Ltd's current assets represent 53.0% of total assets in 2025, an increase from 52.6% in 2017.
- Cash Position: Cash and equivalents constituted 22.2% of total assets in 2025, up from 15.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 13.2% of total assets.
TTY Biopharm Co Ltd Competitors by Total Assets
Key competitors of TTY Biopharm Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Dermapharm Holding SE
XETRA:DMP
|
Germany | €2.27 Billion |
|
China Animal Husbandry Industry Co Ltd
SHG:600195
|
China | CN¥9.32 Billion |
|
Daewoong Pharma
KO:069620
|
Korea | ₩2.26 Trillion |
TTY Biopharm Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.28 | 2.02 | 1.88 |
| Quick Ratio | 1.75 | 1.58 | 1.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$3.37 Billion | NT$2.93 Billion | NT$2.25 Billion |
TTY Biopharm Co Ltd - Advanced Valuation Insights
This section examines the relationship between TTY Biopharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.59 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 4.5% |
| Total Assets | NT$11.35 Billion |
| Market Capitalization | $575.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values TTY Biopharm Co Ltd's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: TTY Biopharm Co Ltd's assets grew by 4.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for TTY Biopharm Co Ltd (2017–2025)
The table below shows the annual total assets of TTY Biopharm Co Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$11.35 Billion ≈ $357.53 Million |
+4.47% |
| 2024-12-31 | NT$10.86 Billion ≈ $342.24 Million |
+10.00% |
| 2023-12-31 | NT$9.87 Billion ≈ $311.11 Million |
+2.86% |
| 2022-12-31 | NT$9.60 Billion ≈ $302.47 Million |
+3.27% |
| 2021-12-31 | NT$9.30 Billion ≈ $292.89 Million |
-0.69% |
| 2020-12-31 | NT$9.36 Billion ≈ $294.92 Million |
-2.01% |
| 2019-12-31 | NT$9.55 Billion ≈ $300.96 Million |
+5.52% |
| 2018-12-31 | NT$9.05 Billion ≈ $285.22 Million |
-4.77% |
| 2017-12-31 | NT$9.51 Billion ≈ $299.52 Million |
-- |
About TTY Biopharm Co Ltd
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers … Read more